ArticleHead and neck pathology2026
Epidemiology and Clinicopathologic Features with Prognostic Implications of Conventional Ameloblastoma: A 22-Year Retrospective Study.
Article in Head and neck pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
backgroundAmeloblastoma is the most common odontogenic neoplasm of the jaws, characterized by locally aggressive behavior and high recurrence potential. Although its clinicopathologic features have been described in global populations, large-scale institutional data from the United States (U.S.) remain limited. This study aims to characterize the epidemiologic and clinicopathologic features of conventional ameloblastoma over a 22-year period and to identify factors associated with recurrence in cases submitted to a single U.S. academic surgical oral pathology laboratory.
methodsA retrospective review was conducted of 123 cases of conventional ameloblastoma submitted to the Surgical Oral Pathology Laboratory at the University of Iowa which receives specimens from various states in the U.S. Data included patient demographics, tumor site, radiographic findings, histologic subtypes, treatment modality, and follow-up information. Recurrence-free survival was analyzed using Kaplan-Meier and log-rank tests, and predictors of recurrence were evaluated by Cox proportional hazards modeling.
resultsAmong the 123 cases, the mean age was 51 years (range: 11-93), and 56.9% were male. Most tumors involved the mandible (91.9%). Of the 90 cases with available radiographic findings, 54.4% were unilocular, 37.8% multilocular, and 7.8% mixed radiolucent–radiopaque. The most common histologic subtype was follicular admixed with other subtypes (61.8%). Among 39 patients with treatment data, 23 (59.0%) underwent resection, 11 (28.2%) had enucleation and curettage, and 5 (12.8%) received enucleation with peripheral ostectomy. Follow-up information was available for 35 patients, of whom 15 (42.9%) experienced recurrence within 8-360 months. Recurrence-free survival differed significantly by treatment modality (p = 0.006), with resection associated with markedly improved outcomes compared with more conservative treatments (adjusted p = 0.028).
conclusionThis study reinforces the importance of surgical treatment selection in the prognosis of conventional ameloblastoma and highlights the need for careful surgical planning to minimize recurrence. Additionally, mixed histopathologic subtypes within the tumor limited the prognostic value of histologic subclassification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.